| Tbio | Protein enabled homolog |
Ena/VASP proteins are actin-associated proteins involved in a range of processes dependent on cytoskeleton remodeling and cell polarity such as axon guidance and lamellipodial and filopodial dynamics in migrating cells. ENAH induces the formation of F-actin rich outgrowths in fibroblasts. Acts synergistically with BAIAP2-alpha and downstream of NTN1 to promote filipodia formation (By similarity).
This gene encodes a member of the enabled/ vasodilator-stimulated phosphoprotein. Members of this gene family are involved in actin-based motility. This protein is involved in regulating the assembly of actin filaments and modulates cell adhesion and motility. Alternate splice variants of this gene have been correlated with tumor invasiveness in certain tissues and these variants may serve as prognostic markers. A pseudogene of this gene is found on chromosome 3. [provided by RefSeq, Sep 2016]
This gene encodes a member of the enabled/ vasodilator-stimulated phosphoprotein. Members of this gene family are involved in actin-based motility. This protein is involved in regulating the assembly of actin filaments and modulates cell adhesion and motility. Alternate splice variants of this gene have been correlated with tumor invasiveness in certain tissues and these variants may serve as prognostic markers. A pseudogene of this gene is found on chromosome 3. [provided by RefSeq, Sep 2016]
Comments
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Leukemia, Myeloid, Acute | 105 | 0.0 | 0.0 |
| Disease | Target Count |
|---|---|
| Leukemia, Myelocytic, Acute | 120 |
| Disease | Target Count | P-value |
|---|---|---|
| non-small cell lung cancer | 2890 | 8.0e-17 |
| astrocytoma | 1146 | 2.4e-16 |
| oligodendroglioma | 2850 | 3.7e-12 |
| ependymoma | 4679 | 5.9e-08 |
| atypical teratoid / rhabdoid tumor | 5112 | 3.7e-06 |
| glioblastoma | 5792 | 4.1e-05 |
| cystic fibrosis | 1696 | 5.6e-05 |
| juvenile dermatomyositis | 1187 | 7.0e-05 |
| medulloblastoma, large-cell | 6241 | 7.6e-05 |
| Astrocytoma, Pilocytic | 3081 | 3.7e-04 |
| Breast cancer | 3578 | 4.6e-04 |
| primitive neuroectodermal tumor | 3035 | 1.4e-03 |
| pediatric high grade glioma | 1064 | 3.3e-03 |
| group 3 medulloblastoma | 4104 | 3.8e-03 |
| osteosarcoma | 7950 | 4.4e-03 |
| invasive ductal carcinoma | 2951 | 6.7e-03 |
| hereditary spastic paraplegia | 318 | 9.9e-03 |
| subependymal giant cell astrocytoma | 2287 | 1.1e-02 |
| active Crohn's disease | 922 | 1.1e-02 |
| ovarian cancer | 8520 | 1.2e-02 |
| lung cancer | 4740 | 1.4e-02 |
| ductal carcinoma in situ | 1745 | 3.7e-02 |
| interstitial lung disease | 298 | 4.5e-02 |
| Disease | log2 FC | p |
|---|---|---|
| active Crohn's disease | 1.022 | 1.1e-02 |
| astrocytoma | 1.300 | 2.4e-16 |
| Astrocytoma, Pilocytic | 1.100 | 3.7e-04 |
| atypical teratoid / rhabdoid tumor | 1.500 | 3.7e-06 |
| Breast cancer | 1.300 | 4.6e-04 |
| cystic fibrosis | -1.276 | 5.6e-05 |
| ductal carcinoma in situ | 1.100 | 3.7e-02 |
| ependymoma | 1.300 | 5.9e-08 |
| glioblastoma | 1.200 | 4.1e-05 |
| group 3 medulloblastoma | 1.700 | 3.8e-03 |
| hereditary spastic paraplegia | -1.580 | 9.9e-03 |
| interstitial lung disease | 1.200 | 4.5e-02 |
| invasive ductal carcinoma | 1.300 | 6.7e-03 |
| juvenile dermatomyositis | 1.070 | 7.0e-05 |
| lung cancer | 1.100 | 1.4e-02 |
| medulloblastoma, large-cell | 1.200 | 7.6e-05 |
| non-small cell lung cancer | 1.304 | 8.0e-17 |
| oligodendroglioma | 1.200 | 3.7e-12 |
| osteosarcoma | 1.363 | 4.4e-03 |
| ovarian cancer | 1.500 | 1.2e-02 |
| pediatric high grade glioma | 1.100 | 3.3e-03 |
| primitive neuroectodermal tumor | 1.100 | 1.4e-03 |
| subependymal giant cell astrocytoma | 1.633 | 1.1e-02 |
MSEQSICQARAAVMVYDDANKKWVPAGGSTGFSRVHIYHHTGNNTFRVVGRKIQDHQVVINCAIPKGLKY 1 - 70 NQATQTFHQWRDARQVYGLNFGSKEDANVFASAMMHALEVLNSQETGPTLPRQNSQLPAQVQNGPSQEEL 71 - 140 EIQRRQLQEQQRQKELERERLERERMERERLERERLERERLERERLEQEQLERERQERERQERLERQERL 141 - 210 ERQERLERQERLDRERQERQERERLERLERERQERERQEQLEREQLEWERERRISSAAAPASVETPLNSV 211 - 280 LGDSSASEPGLQAASQPAETPSQQGIVLGPLAPPPPPPLPPGPAQASVALPPPPGPPPPPPLPSTGPPPP 281 - 350 PPPPPLPNQVPPPPPPPPAPPLPASGFFLASMSEDNRPLTGLAAAIAGAKLRKVSRMEDTSFPSGGNAIG 351 - 420 VNSASSKTDTGRGNGPLPLGGSGLMEEMSALLARRRRIAEKGSTIETEQKEDKGEDSEPVTSKASSTSTP 421 - 490 EPTRKPWERTNTMNGSKSPVISRRDSPRKNQIVFDNRSYDSLHRPKSTPLSQPSANGVQTEGLDYDRLKQ 491 - 560 DILDEMRKELTKLKEELIDAIRQELSKSNTA 561 - 591 //
